sur Evotec AG (NASDAQ:EVTCY)
Evotec Advances Neuroscience Partnership with Bristol Myers Squibb
Evotec SE has announced significant progress in its strategic partnership with Bristol Myers Squibb. This advancement bolsters the joint neuroscience pipeline and involves a payment of US$25 million to support further research.
The collaboration, initiated in December 2016, aims to discover treatments for neurodegenerative diseases. The progress leverages Evotec’s PanOmics platform and patient-derived disease models. This platform is one of the largest in the industry.
The partnership has already produced a promising pipeline. A key achievement was the in-licensing of EVT8683 by Bristol Myers Squibb in 2021. Earlier this year, the partnership was extended for an additional 8 years.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, highlighted the productive nature of the partnership and expressed excitement about advancing yet another program towards clinical development in 2026.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Evotec AG